無料プレビュー

Royalty Pharma plc (RPRX) · NASDAQ

プロフィール

Royalty Pharma plc is the largest buyer of biopharmaceutical royalties, acquiring contractual rights to payments based on top-line sales of approved and development-stage therapies. The company holds royalties on more than 35 marketed products including Trikafta, Trelegy, Tysabri, and Evrysdi, plus 20 development-stage candidates. It operates through third-party royalty acquisitions, synthetic royalties on approved therapies, and other funding modalities including debt and equity investments. Royalty Pharma serves biopharmaceutical companies, academic institutions, and non-profits across all t

主要指標

株価: $56.21 (-0.97%)
時価総額: 249億ドル
PER（今期予想）: 10.5
PBR: 3.7
配当利回り: 1.65%
52週レンジ: $35.23 – $64.38
業種: Healthcare / Medical - Pharmaceuticals
上場: NASDAQ
構成銘柄: —

比較会社: RGLD Royal Gold, Inc.、CORT Corcept Therapeutics Incorporated、WBA Walgreens Boots Alliance, Inc.、OR OR Royalties Inc.、KNSA Kiniksa Pharmaceuticals International, plc、LQDA Liquidia Corporation、PBH Prestige Consumer Healthcare Inc.、LTGO Latigo Biotherapeutics Inc.

長期トレンド・直近動向・強気／弱気シナリオ・業績10年・バリュエーション・テクニカル・株主・役員・深掘り分析は会員向けです。

7日間無料で全文を読むログイン

次回決算: 2026-11-04 · 更新: 2026-10-09